Featured Research

from universities, journals, and other organizations

Overcoming tumor resistance to anti-cancer agent TRAIL

Date:
March 22, 2010
Source:
Rockefeller University Press
Summary:
The TRAIL ligand is a promising anti-cancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential. According to a new study, small molecules known to block Mcl-1 might represent a suitable means to overcome TRAIL resistance.

The TRAIL ligand is a promising anticancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential.

Related Articles


According to a study in the March 22 issue of the Journal of Cell Biology, small molecules known to block Mcl-1 (induced myeloid leukemia cell differentiation protein) might represent a suitable means to overcome TRAIL resistance.

Researchers know that TRAIL-induced cell death entirely depends on the presence of Bax, which is a member of the proapoptotic Bcl-2 family of proteins and is often lost in tumor cells for various reasons. Despite the expression of Bak, another protein that promotes dell death, Bax-deficient cells are resistant to TRAIL-induced death.

Peter Daniel (Humboldt University, Germany) and colleagues investigate the role of two Bcl-2 proteins -- Mcl-1 and Bcl-xL -- that keep Bak in check. The team's findings show that blocking Mcl-1 but not Bcl-xL overcame resistance to TRAIL-induced cell death in bax-deficient cells and enabled TRAIL to activate Bak. Blocking Bak inhibitors like Mcl-1 appears to be a promising strategy in limiting the resistance of cancers to TRAIL.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. B. Gillissen, J. Wendt, A. Richter, A. Richter, A. Muer, T. Overkamp, N. Gebhardt, R. Preissner, C. Belka, B. Dorken, P. T. Daniel. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. The Journal of Cell Biology, 2010; 188 (6): 851 DOI: 10.1083/jcb.200912070

Cite This Page:

Rockefeller University Press. "Overcoming tumor resistance to anti-cancer agent TRAIL." ScienceDaily. ScienceDaily, 22 March 2010. <www.sciencedaily.com/releases/2010/03/100322092045.htm>.
Rockefeller University Press. (2010, March 22). Overcoming tumor resistance to anti-cancer agent TRAIL. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/03/100322092045.htm
Rockefeller University Press. "Overcoming tumor resistance to anti-cancer agent TRAIL." ScienceDaily. www.sciencedaily.com/releases/2010/03/100322092045.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins